Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial

The Lancet Haematology 2026

View at publisher
Authors: Esther Natalie Olíva, Francesco Cottone, Sudhir K. Unni, Anne Correges, Jes Birger Hansen, Xiaocong Li Marston, Jorge Cortes, Mikkael Aaron Sekeres
DOI: 10.1016/s2352-3026(25)00361-8
Cited by: 0
References: 22

Fields of Study & Subjects

Acute Myeloid Leukemia Research Cancer survivorship and care Retinoids in leukemia and cellular processes

Publication details

Journal / source
The Lancet Haematology
Volume
13
Issue
3
Pages
e169–e180
Publication date
1 March 2026
Language
EN